478 related articles for article (PubMed ID: 35263569)
1. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8
Banta KL; Xu X; Chitre AS; Au-Yeung A; Takahashi C; O'Gorman WE; Wu TD; Mittman S; Cubas R; Comps-Agrar L; Fulzele A; Bennett EJ; Grogan JL; Hui E; Chiang EY; Mellman I
Immunity; 2022 Mar; 55(3):512-526.e9. PubMed ID: 35263569
[TBL] [Abstract][Full Text] [Related]
2. CD8
Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
[TBL] [Abstract][Full Text] [Related]
3. CD226
Jin HS; Ko M; Choi DS; Kim JH; Lee DH; Kang SH; Kim I; Lee HJ; Choi EK; Kim KP; Yoo C; Park Y
Cancer Immunol Res; 2020 Jul; 8(7):912-925. PubMed ID: 32265229
[TBL] [Abstract][Full Text] [Related]
4. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
5. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
6. CD226 opposes TIGIT to disrupt Tregs in melanoma.
Fourcade J; Sun Z; Chauvin JM; Ka M; Davar D; Pagliano O; Wang H; Saada S; Menna C; Amin R; Sander C; Kirkwood JM; Korman AJ; Zarour HM
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046006
[TBL] [Abstract][Full Text] [Related]
7. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
[No Abstract] [Full Text] [Related]
8. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Johnston RJ; Comps-Agrar L; Hackney J; Yu X; Huseni M; Yang Y; Park S; Javinal V; Chiu H; Irving B; Eaton DL; Grogan JL
Cancer Cell; 2014 Dec; 26(6):923-937. PubMed ID: 25465800
[TBL] [Abstract][Full Text] [Related]
9. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade.
Yoo KJ; Johannes K; González LE; Patel A; Shuptrine CW; Opheim Z; Lenz K; Campbell K; Nguyen TA; Miriyala J; Smith C; McGuire A; Tsai YH; Rangwala F; de Silva S; Schreiber TH; Fromm G
J Immunol; 2022 Aug; 209(3):510-525. PubMed ID: 35817517
[TBL] [Abstract][Full Text] [Related]
10. Perturbed CD8
Tauriainen J; Scharf L; Frederiksen J; Naji A; Ljunggren HG; Sönnerborg A; Lund O; Reyes-Terán G; Hecht FM; Deeks SG; Betts MR; Buggert M; Karlsson AC
Sci Rep; 2017 Jan; 7():40354. PubMed ID: 28084312
[TBL] [Abstract][Full Text] [Related]
11. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
Chiang EY; Mellman I
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
[TBL] [Abstract][Full Text] [Related]
12. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
Front Immunol; 2021; 12():699895. PubMed ID: 34367161
[TBL] [Abstract][Full Text] [Related]
13. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
[TBL] [Abstract][Full Text] [Related]
14. Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis.
Deng C; Li W; Fei Y; Wang L; Chen Y; Zeng X; Zhang F; Li Y
Front Immunol; 2020; 11():1619. PubMed ID: 32793241
[TBL] [Abstract][Full Text] [Related]
15. TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit.
Pauken KE; Wherry EJ
Cancer Cell; 2014 Dec; 26(6):785-787. PubMed ID: 25490444
[TBL] [Abstract][Full Text] [Related]
16. Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients.
Li C; Liu H; Duan Z
BMC Immunol; 2024 Feb; 25(1):12. PubMed ID: 38326745
[TBL] [Abstract][Full Text] [Related]
17. TIGIT/CD226 Axis Regulates Anti-Tumor Immunity.
Yeo J; Ko M; Lee DH; Park Y; Jin HS
Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33670993
[TBL] [Abstract][Full Text] [Related]
18. Human CD4
Šunina M; Alnek K; Kisand K; Uibo R
Scand J Immunol; 2021 Sep; 94(3):e13089. PubMed ID: 35971920
[TBL] [Abstract][Full Text] [Related]
19. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
20. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
